Home > Riviste > Panminerva Medica > Fascicoli precedenti > Panminerva Medica 2005 December;47(4) > Panminerva Medica 2005 December;47(4):219-28

ULTIMO FASCICOLO
 

JOURNAL TOOLS

eTOC
Per abbonarsi PROMO
Sottometti un articolo
Segnala alla tua biblioteca
 

ARTICLE TOOLS

Estratti
Permessi

 

REVIEWS   

Panminerva Medica 2005 December;47(4):219-28

Copyright © 2009 EDIZIONI MINERVA MEDICA

lingua: Inglese

Management of the metabolic syndrome

Grant R. W., Meigs J. B.

General Medicine Division Department of Medicine Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA


PDF


The metabolic syndrome (MetS) represents the co-occurrence of insulin resistance, hypertension, central adiposity, atherogenic dyslipidemia, and a pro-inflammatory and pro-thrombotic state. Patients with this syndrome are at increased risk for the development of type 2 diabetes mellitus and cardiovascular disease. Epidemiologic studies reveal a prevalence of the MetS that increases with age and obesity. Patients with the MetS should be recognized as being at high risk for cardiovascular complications. Ongoing research focuses on the underlying pathophysiology of this disorder and the use of drug therapy to directly target insulin resistance and endothelial dysfunction. Currently, the standard of care includes active identification and aggressive management of traditional cardiovascular risk factors with an emphasis on healthy lifestyle changes to reduce weight and increase physical fitness.

inizio pagina